Iron overload is a metabolic disorder characterized by excessive iron deposition in the liver,pancreas,heart,endocrine organs, etc.,resulting in structural damage and dysfunction.The liver is the primary organ for iron storage,and excessive iron deposition induces liver inflammation and fibrosis,which may progress to cirrhosis and even liver cancer,with a poor prognosis.Accurate evaluation and effec-tive treatment can reduce liver injury caused by iron overload and improve patients′survival.

Through tracing to the source of syndrome differentiation according to meridian and collateral theory, Lingshu: Jingmai (Miraculous Pivot * Meridians) is studied in this article. Considered the requirement and concept of treatment according to syndrome differentiation, the application of proper syndrome differentiation methods based on meridian and collateral theory in acupuncture clinic is discussed. Theories, key factors as well as historical relations of syndrome differentiation according to meridian and collateral are also analyzed. The feature and origin of syndrome differentiation according to meridian and collateral, which are considered to be more important, are also discussed. Focuses of explanation are put on the functions, significances, connotations, relationship and clinical application of two major factors of syndrome differentiation, namely the running course of meridian and collateral and signs.
Acupuncture Therapy ; Diagnosis, Differential ; Humans ; Meridians ; Syndrome

Objective To optimize the extraction conditions for Yuemu eye drops.Methods The extraction conditions were studied with orthogonal test L_9(3~4),the content of caffeic acid was determined by HPLC as index.Results Alcohol concentration and frequency of extraction were remarkable factors in the test. Conclusion The optimum extraction technology for Yuemu eye drops was to reflux and extract the materials for 2 times in 80% alcohol,the volume of which was 6 times the weight of herbal medicine,with 1 hour for each time.

To synthesize 3-nicotinamide-1, 2, 4-benzotriazine-1, 4-dioxide and to determine its anti-tumor activity in vitro. METHODS: Cyanogenamide and benzofuroxan were used as starting materials to prepare the intermediate (3-amino-1, 2, 4-benzotriazine-1, 4-dioxide, Tirapazamine). The objective substance was obtained from the reaction of the intermediate and nicotinic acyl chloride. The in vitro antitumor activities of the synthesized compounds were determined by MTT method using MCF-7 and HepG2 cells. RESULTS: The obtained compounds were identified by 1H-NMR, MS and IR. The purity of the objective substance determined by HPLC was 99.24%. CONCLUSION: The anti-tumor activity of 3-nicotinamide-1, 2, 4-benzotriazine-1, 4-dioxide is much better than tirapazamine. Copyright 2012 by the Chinese Pharmaceutical Association.

OBJECTIVE: To study the effects of total saponins of Panax japonicus (TSPJ) on human leukemic HL-60 cells. METHODS: Human leukemic HL-60 cells were cultured in vitro. The cancer cell vigor was detected by using cell counting kit-8. Nitroblue tetrazolium (NBT) was used for measuring cell reduction. The cell cycle and the expression of differentiation antigen CD11b were detected by flow cytometry. RESULTS: Compared with the negative control group, TSPJ in different concentrations could decrease the vigor of HL-60 cells and the number of cells in S phase and up-regulate the CD11b expression, while the numbers of NBT positive cells and cells in G(0)/G(1) phase in the different concentrations of TSPJ-treated groups were increased. CONCLUSION: TSPJ can inhibit the HL-60 cell growth in vitro. Its mechanism may be related to inhibiting proliferation and inducing cell differentiation and cycle arrest.

Objective To investigate the effect of lectin like oxidized low density lipoprotein receptor 1 ( LOX-1 ) in NRK52E intaking lipid induced by oxidized low density lipoprotein ( ox-LDL). Methods NRK-52E was incubated with ox-LDL (0,25,50, and 100 g/ml ) for 24 hours or pre-treated with the chemical blocker of LOX-1 receptor- polyI or carrageenan, and then exposed to 50 μg/ml of ox-LDL. LOX-Ⅰ mRNA was examined by real-time PGR. LOX-1 protein was assessed by Western blot analysis. Lipid deposit was examined by oil red O. Results LOX-1 mRNA expression in 25,50,100 μg/ml ox-LDL group was 2. 13, 10. 14, 20. 81 times of that in 0 g/ml ox-LDL group ( P <0. 05 ,respectively). LOX-1 protein expression in 25,50,100 μg/ml ox-LDL group was 2. 53,12. 18,21.45 times of that in 0 μg/ml ox-LDL group( P <0. 05 ,respectively). Following the increased LOX-1, lipid intake increased. Pre-treatment with Poly Ⅰ or carrageenan, LOX-1 mRNA expression deceased by 48% or 47%, LOX-1 protein deceased by 72% or 65%, lipid intake induced by 41% or 49% ( P <0.05 ,respectively). Lipid had a close relationship with LOX-1 ( r = 0. 87, P < 0. 05). Conclusion Ox-LDL induced NRK52E to express LOX-1 and promoted NRK52E to intake lipid, and this effect could be partly blocked by LOX-1 blocker.

Eleven elderly patients undergoing maintenance hemodialysis without ARB or ACEI within 4 weeks were enrolled. Anti-hypertensive agents were replaced by telmisartan gradually to maintain stable blood pressure. Before and after 6 or 12 weeks of treatment, blood biochemical profiles, fasting blood glucose, fasting plasma insulin, insulin resistance index(HOMA-IR), blood pressure, and body weight were recorded. Our results showed that telmisartan did not affect body weight, high-density lipoprotein (HDL), triglyceride (TG), SCr, BUN, Alb, K+ , and PTH, although led to a significant decrease in TC and low-density lipoprotein (LDL). Following telmisartan treatment, FPG did not change significantly, but fasting insulin decreased from 13.9±3.6 mU/ml to 9.9±2.7 or 9.1±2.3 mU/ml at 6 and 12 week (P<0.01), and HOMA-IR decreased from 3.5±1.4 to 2.4±0.8 or 2.2±0.8 at 6 and 12 week (P<0.05). These results suggest that insulin resistance in elderly patients with MHD may be improved by telmisartan.

OBJECTIVE:To promote the adjustment of National Essential Drug List and implementation of Essential Drug List. METHODS:National Essential Drug List was compared with Essential Drug List issued by WHO. Retrieved from statistical results conducted by State Food and Drug Administration, the problem that there were large number of drug in China while little category were included in National Essential Drug List was analyzed, according to practice in China. RESULTS & CONCLUSION: Drug enterprises increased the dosage form and category of preparation blindly because of huge raw drug market, various dosage forms and weak administration to drug enterprises. The characteristics of drug were cheap, high quality, acceptance by state, which decided that the category of drug in Essential Drug List should not be too much. It is necessary to adjust Essential Drug List as the change of situation so as to meet the requirement of public health.

Objective To find out nutrient support drug utilization in cancer patients in our hospital. Methods An analysis was made by means of drug utilization research into the structure and rationality of nutrient support drug utilization in our hospital through an investigation into the detailed records of the dispensary from 1999 to 2002 and into 1 014 medical records from 2002. Results The variety, quantity, and cost of nutrient support drug utilization in the four years rose respectively by 58.82%, 71.66% and 28.16%. 49.30% of the cancer patients whose medical records were surveyed used such drugs. The quantity and person time ratio of PN and EN drug utilization was respectively 14∶1 and 13∶1, with malnourished patients accounting for 19.80%. Of the PN drugs whose DDD value could be determined, most had a DUI value that was greater than 1 whereas most of the EN drugs had a DUI value which was smaller than 1. Conclusion The variety, quantity, and cost of nutrient support drug utilization in the four years rose rapidly. The quantity and person time of PN drug utilization were much higher than those of EN drug utilization. Doubts could be cast in the handling of indications for nutrient support drug utilization in some patients and the doses of some nutrient support drugs prescribed were not so rational. Further explorations need to be made into the rational application of nutrient support treatment.

Due to unknown onset time, patients with wake-up stroke and unknown onset stroke areoften excluded from thrombolytic therapy. However, many clinical studies have shown that multimodal imaging techniques can effectively guide wake-up stroke and unknown onset stroke for intravenous thrombolysis. Its endovascular treatment has also made some progress. This article mainly reviews the imaging findings, intravenous thrombolysis, and endovascular therapy in patients with wake-up stroke and unknown onset stroke.